DUBLIN--(BUSINESS WIRE)--
ICON plc, (NASDAQ: ICLR) a global provider of outsourced
development services to the pharmaceutical, biotechnology and medical
device industries, today announced that Dr. Steve Cutler has been
appointed to the newly created position of Chief Operating Officer
(COO), ICON plc.
Dr. Cutler joined ICON in November 2011 as Group President, Clinical
Research Services. In his new role as COO, Dr. Cutler has responsibility
for all of ICON's operational units, covering Early Phase, Clinical,
Laboratories, Commercialisation and Outcomes and DOCS FSP & resourcing.
Dr Cutler will also take responsibility for ICON's sales and marketing
and strategic alliance teams.
Within Dr. Cutler's team, Dr. Nuala Murphy has been appointed President,
ICON Clinical Services and Mr. Jim Miskel has been appointed Executive
Vice President & General Manager, ICON Laboratory Services.
Dr. Murphy joined ICON in 2012 as Executive Vice President, Global
Clinical Operations and Data Management, bringing to ICON over 22 years'
experience within the pharmaceutical and CRO industries. In her new
role, Dr. Murphy will oversee ICON's global clinical services,
comprising clinical and data operations, study start-up, project
management, clinical risk management, technology services and clinical
scientific operations.
Mr. Miskel joined ICON in November 2013 and will lead ICON's newly
combined Central and Bioanalytical laboratories group. He brings a
wealth of laboratory and pharmaceutical industry experience to ICON,
having previously held senior positions with Harlan Laboratories, MDS
Pharma Services, Wyeth Pharmaceuticals and McKinsey & Company.
Commenting on the appointments, Ciaran Murray, Chief Executive Officer,
ICON plc, said: "We continually review our structure to ensure that as
the market evolves, our organisation can continue to provide customers
with innovative and integrated solutions across our various service
lines and business units. Bringing all operational units under Steve's
leadership will allow us to further enhance the support we can offer to
our customers' development programs. I would like to congratulate Steve,
Nuala and Jim on their new roles and wish them every success in the
future."
About ICON plc
ICON plc is a global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries. The Company
specialises in the strategic development, management and analysis of
programs that support clinical development - from compound selection to
Phase I-IV clinical studies. ICON currently has approximately 10,300
employees, operating from 77 locations in 38 countries.
Further information is available at www.iconplc.com
This press release contains forward-looking statements. These statements
are based on management's current expectations and information currently
available, including current economic and industry conditions. These
statements are not guarantees of future performance or actual results,
and actual results, developments and business decisions may differ from
those stated in this press release. The forward-looking statements are
subject to future events, risks, uncertainties and other factors that
could cause actual results to differ materially from those projected in
the statements, including, but not limited to, the ability to enter into
new contracts, maintain client relationships, manage the opening of new
offices and offering of new services, the integration of new business
mergers and acquisitions, as well as economic and global market
conditions and other risks and uncertainties detailed from time to time
in SEC reports filed by ICON, all of which are difficult to predict and
some of which are beyond our control. For these reasons, you should not
place undue reliance on these forward-looking statements when making
investment decisions. The word "expected" and variations of such words
and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.
ICON/ICLR-G
ICON Media Contact
Genevieve Tuck
Weber Shandwick
Tel:
+44 (0)20 7067 0655
gtuck@webershandwick.com
Source: ICON
News Provided by Acquire Media
